{"title":"Yellow fever vaccination and the thymus in adults with congenital heart disease","authors":"Ella McDonnell , Hajar Habibi","doi":"10.1016/j.ijcchd.2024.100494","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>To highlight the potential lack of documentation of thymectomy on historic cardiac operation notes and how this impacts the safety of the yellow fever vaccination for patients who have had congenital heart surgery in childhood.</p></div><div><h3>Background</h3><p>With advances in treatment, the population of adults with congenital heart disease (ACHD) is ever growing. Consequently, increasing numbers of patients wish to travel and work abroad. In recent years, this has presented a unique challenge in terms of the safety of the yellow fever vaccine in this patient group.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266666852400003X/pdfft?md5=c45e784c784ce9dbffff714fe9a0a91d&pid=1-s2.0-S266666852400003X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of cardiology. Congenital heart disease","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266666852400003X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Aim
To highlight the potential lack of documentation of thymectomy on historic cardiac operation notes and how this impacts the safety of the yellow fever vaccination for patients who have had congenital heart surgery in childhood.
Background
With advances in treatment, the population of adults with congenital heart disease (ACHD) is ever growing. Consequently, increasing numbers of patients wish to travel and work abroad. In recent years, this has presented a unique challenge in terms of the safety of the yellow fever vaccine in this patient group.